Levetiracetam-induced cutaneous adverse drug reactions were not associated with HLA genes in a small sample of Chinese patients with epilepsy
Introduction
Levetiracetam (LEV) was first approved by United States Food and Drug Administration (US FDA) in December 1999 and proved to be effective in both partial and generalized epilepsy syndromes either as adjunctive treatment or monotherapy (Berkovic et al., 2007, French and Pedley, 2008). Unlike other antiepileptic drugs (AEDs), LEV has unique structural feature, novel antiepileptic mechanism and also fewer adverse side effects. One of the most common adverse reactions, AEDs-induced cutaneous adverse drug reactions (cADRs), has been less reported in LEV. To the best of our knowledge, only some scattered case reports of LEV-induced cADRs can be retrieved. The clinical characteristics and genetic mechanisms of LEV-induced cADRs have been unclear.
Recent advances in pharmacogenomics of AEDs may bring us some inspirations. Accumulated evidence confirmed the closely association between some AEDs-induced cADRs and the human leukocyte antigen (HLA) genes. Several important biological markers, including HLA-B*1502 allele (Chung et al., 2004) and HLA-A*3101 allele (McCormack et al., 2011), have been found to have outstanding predictive value for specific AEDs-induced cADRs in different populations. In the present study, we investigated the clinical features of nine epilepsy patients who experienced LEV-induced cADRs and exploratorily examine the possible association of the HLA genes with the risk of LEV-induced cADRs in Chinese Han populations.
Section snippets
Patients
Nine cases with LEV-induced cADRs from epilepsy center of West China Hospital (8 from outpatient clinic and 1 from the ward) were included between September 2011 and December 2014. The diagnostic criteria for the patient group were: subjects who developed LEV-induced maculopapular exanthema (MPE) after taking LEV for less than eight weeks. Patients who developed MPE after simultaneously use of other suspicious drugs were excluded. Other common causes of cADRs including over-the-counter drugs,
Clinical characteristics
Nine epileptic patients (6 male, 3 female) with LEV-induced cADRs and 36 LEV-tolerant controls were included. LEV was taken as monotherapy for epilepsy in four patients while as adjunctive treatment in the rest. All of the skin rashes were confirmed as MPE. Routine laboratory examination and temperature were normal. Severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), were not observed. All nine patients had the rashes
Discussion
LEV, a new generation antiepileptic drug, with novel anticonvulsive mechanism (Hovinga, 2001), is structurally similar to piracetam which is one of the most common nootropic drugs, but different from other currently marketed AEDs. LEV is characterized with insignificant drug interactions and favorable tolerability and safety profile (Lo et al., 2011, Lyseng-Williamson, 2011). The reported adverse effects profile of LEV include somnolence, headache, asthenia, fatigue, dizziness, behavioural
Disclosure
None of the authors has any conflict of interest to disclose.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (No. 81171301). We thank all subjects who participated in this study.
References (19)
- et al.
Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population
Epilepsy Res.
(2010) - et al.
Antiepileptic drug-induced skin reactions: a retrospectivestudy and analysis in 3793 Chinese patients with epilepsy
Clin. Neurol. Neurosurg.
(2012) - et al.
Stevens-Johnson syndrome induced by levetiracetam
Seizure
(2012) - et al.
Comparison and predictors of rash associated with 15 antiepileptic drugs
Neurology
(2007) - et al.
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
Neurology
(2007) - et al.
Medical genetics: a marker for Stevens-Johnson syndrome
Nature
(2004) - et al.
Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases
JAMA Dermatol.
(2013) Dresssyndrome induced by levetiracetam
J. Eur. Acad. Dermatol. Venereol.
(2015)- et al.
Clinical practice. Initial management of epilepsy
N. Engl. J. Med.
(2008)
Cited by (0)
- 1
These authors contributed equally to this work.